Although some characteristics such as the status of p53 mutation or upregulation of class III tubulin, annexin A3, or bcl-2 have been reported to be potential indicators of chemoresistance [9–12], there are no promising biomarkers that predict chemoresistance in ovarian cancer patients. Here, TP53 is linked to ovarian cancer.